These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 16224447)
21. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents. Ozols RF J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247 [TBL] [Abstract][Full Text] [Related]
22. Evaluation of cisplatin and cyclosporin A in recurrent platinum-resistant ovarian cancer: a phase II study of the gynecologic oncology group. Manetta A; Blessing JA; Hurteau JA Gynecol Oncol; 1998 Jan; 68(1):45-6. PubMed ID: 9454659 [TBL] [Abstract][Full Text] [Related]
23. The association of taxane resistance genes with the clinical course of ovarian carcinoma. Ehrlichova M; Mohelnikova-Duchonova B; Hrdy J; Brynychova V; Mrhalova M; Kodet R; Rob L; Pluta M; Gut I; Soucek P; Vaclavikova R Genomics; 2013 Aug; 102(2):96-101. PubMed ID: 23542236 [TBL] [Abstract][Full Text] [Related]
24. [A recurrent ovarian cancer patient who achieved a complete response following irinotecan plus CDDP therapy]. Kawashima T; Murakami H; Kanamori T; Nakamura Y Gan To Kagaku Ryoho; 2007 Mar; 34(3):461-3. PubMed ID: 17353644 [TBL] [Abstract][Full Text] [Related]
25. Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance. Ferriss JS; Kim Y; Duska L; Birrer M; Levine DA; Moskaluk C; Theodorescu D; Lee JK PLoS One; 2012; 7(2):e30550. PubMed ID: 22348014 [TBL] [Abstract][Full Text] [Related]
26. Molecular targets of ovarian carcinomas with acquired resistance to platinum/taxane chemotherapy. Kurzeder C; Sauer G; Deissler H Curr Cancer Drug Targets; 2006 May; 6(3):207-27. PubMed ID: 16712458 [TBL] [Abstract][Full Text] [Related]
27. New options for the treatment of advanced ovarian cancer. Dunton CJ Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739 [TBL] [Abstract][Full Text] [Related]
35. A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer. Wolf JK; Bodurka DC; Verschraegen C; Sun CC; Branham D; Jenkins AD; Atkinson N; Gershenson DM Gynecol Oncol; 2006 Sep; 102(3):468-74. PubMed ID: 16516276 [TBL] [Abstract][Full Text] [Related]
36. Docetaxel in the management of ovarian cancer. Blagden SP; Kaye SB Expert Rev Anticancer Ther; 2005 Apr; 5(2):203-14. PubMed ID: 15877518 [TBL] [Abstract][Full Text] [Related]
37. Prediction of Chemotherapy Response With Platinum and Taxane in the Advanced Stage of Ovarian and Uterine Carcinosarcoma: A Clinical Implication of In vitro Drug Resistance Assay. Matsuo K; Bond VK; Im DD; Rosenshein NB Am J Clin Oncol; 2010 Aug; 33(4):358-63. PubMed ID: 19875949 [TBL] [Abstract][Full Text] [Related]